Skip to content
DataLookout
Menu

MOST-ExpressNCT07936422

A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response Rate at 18 weeks (ORR-18W)
Timeframe: 18 weeks after treatment start

Secondary (7)

Duration of Response (DoR)
Progression Free Survival (PFS)
Progression Free Rate at 18W (PFR-18W)
Overall Survival (OS)
Safety as per NCI-CTCAE V6.0
Show 2 moreShow less
EQ-5D-5L questionnaire
Length of hospital stays (LOS) including acute care hospitalizations? home care hospitalizations and follow-up and rehabilitation care

Arms and interventions

Trastuzumab deruxtecanExperimental

HER2-targeted antibody-drug conjugate

Drugs: Trastuzumab Deruxtecan for Injection (T-DXd)

Sites

6 sites in 1 country